WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | February 24, 2022

Filamentous fungi of the phylum Basidiomycota are considered as an attractive source for the biotech‑ nological production of composite materials. The ability of many basidiomycetes to accept residual lignocellulosic plant biomass from agriculture and forestry.

whitePaper | February 3, 2023

Imaweld® is thermoplastic elastomer tubing particularly designed to transfer critical fluid in pharmaceutical and biopharmaceutical applications.

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

whitePaper | December 15, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.